31 |
Clinical study on apolipoprotein E distribution, metabolism and glycationLiu, Yifen January 2015 (has links)
Apolipoproteins have important roles in the transport of lipids and the regulation of lipoprotein metabolism as cofactors for enzymes and ligands for receptor-binding. Their function and metabolism are closely related to the development of many diseases. This dissertation describes the investigation of the distribution and metabolism of apoE and glycated apoE in diabetes, obesity and hyperlipidaemia in comparison with healthy people. In order to carry out the research, I developed several robust laboratory methods and techniques for the isolation and measurement of apoE and glycated apoE. These included (1) a modified in-house ultracentrifugation for isolation of lipoprotein fractions (2) high sensitivity sandwich enzyme-linked immunosorbent assay (ELISA) for apoE and (3) m-aminophenylboronate affinity chromatography for the separation of glycated and non- glycated apoE.In healthy people the apoE concentration in different lipoprotein fractions is influenced by age, gender and apoE genotype. The effect of atorvastatin on serum apoE concentration in patients with type 2 diabetes with nephropathy was dependent on the dose of atorvastatin and apoE genotype and was strongly correlated with the reduction in triglycerides (TG) in very low density lipoprotein (VLDL).The effect of bariatric surgery on obese patients with and without diabetes demonstrated that after bariatric surgery, VLDL-apoE increased and apoE in low density lipoprotein (LDL), high density lipoprotein (HDL) and d>1.21g/ml fractions decreased; both glycated LDL-apoE and glycated HDL-apoE decreased. Total apoE and glycated apoE concentrations in plasma decreased to levels comparable to those of healthy controls. However, the distribution within the lipoprotein fractions was very different. The effect of niacin/laropiprant (LRPT) on lipoproteins in hyperlipidaemia patients was assessed in a blind crossover trial. Niacin/LRPT slightly decreased VLDL-apoE and LDL-apoE. It had no effect on apoE in HDL. Glycated apoE did not change in hyperlipidaemia. These results show that, compared with healthy people, the apoE distribution in obese and hyperlipidaemia patients is abnormal despite no change in total apoE concentration in some cases. The results also demonstrate that glycated apoE originates preferentially from VLDL. Various mechanisms for these results and relationships with other lipids are discussed. Furthermore, I suggest several potential directions, especially in vitro, for further research on apoE function and metabolism.
|
32 |
Understanding the Role of the Receptor for Advanced Glycation End-Products (Rage) in Pancreatic CancerSwami, Priyanka January 2019 (has links)
Expression of the Receptor for Advanced Glycation End Products (RAGE) and is upregulated in a several cancers. Based on published studies, we hypothesized that RAGE, when overexpressed in pancreatic cancer cells, will promote cell proliferation and migration. To study the role of RAGE in pancreatic cancer, we selected the human pancreatic cancer cell-line PANC-1, and stably transfected the cells with full length RAGE to generate model cell-lines that overexpress RAGE. We obtained two cell-lines PANC-1 FLR2 and PANC-1 FLR3 and examined the influence of RAGE on cellular properties. A significant increase in proliferation but a reduction in migratory abilities of PANC-1 FLR2 and PANC-1 FLR3 cells was observed. The increase in proliferation and reduction in migration was reverted upon knockdown of RAGE in PANC-1 FLR2 cells with siRNA specific for RAGE. The reduction in migration was supported by the reduced levels of vimentin and several integrins in RAGE transfected cells. Furthermore, we observed a downregulation in FAK, AKT, ERK1/2 and NF-κB activity.
Growing evidence supports that RAGE is essential for pancreatic cancer progression. It has also been shown that RAGE facilitates pancreatic tumor cell survival by enhancing autophagy and inhibiting apoptosis. The goal of our study was to determine the effect of RAGE inhibition during gemcitabine chemotherapy on the growth of pancreatic tumor. Hence, we investigated the effect of RAGE inhibitors and their combination with gemcitabine in an orthotopic mouse model of pancreatic cancer using mouse pancreatic cancer cell-line KPC 5508. We used two RAGE inhibitors, an anti-RAGE monoclonal antibody (IgG2A11) and a small molecule RAGE inhibitor (FPS-ZM1). We observed a significant reduction in tumor weights of the mice treated with the combination of IgG2A11 and gemcitabine as compared to gemcitabine alone treated mice. The reduction in tumor growth was accompanied with increase in p62 levels (marker of autophagy) and increase in levels of cleaved PARP (marker of apoptosis). We also observed reduction in HMGB1 and phosphorylation levels of ERK1/2 in tumors from the group treated with the combination as compared to the gemcitabine alone treated group. / North Dakota State University. College of Health Professions / NIH Grant # P20 GM109024 from the National Institute of General Medicine
|
33 |
Glycated Bovine Serum Albumin for Curcumin Nanoencapsulation: Bio-Nano InteractionsPfeilsticker Neves, Renata 26 August 2021 (has links)
Glycation of whey proteins results in food-grade composites with modified physicochemical properties. Here, the reaction between glucose and bovine serum albumin (BSA) is promoted under wet-heating conditions. The glycated protein is characterized in depth and compared to the native counterpart and the impact of glycation on properties like net surface charge, particle size and surface hydrophobicity are observed. Conjugation with glucose reduced the surface hydrophobicity of BSA but the interactions between albumin and curcumin became stronger, which contradicts the direct relationship between curcumin binding affinity and protein surface hydrophobicity described in the literature. Nonetheless, curcumin was still capable of quenching the intrinsic fluorescence of the protein after conjugation with glucose and leads to the conclusion that curcumin and BSA interact in a different manner upon glycation. This thesis also depicts mucin as a forthcoming model in the study of nanoparticle interactions with intestinal mucus and glycation posed no effect on such interactions.
|
34 |
The role of advanced glycation end products on sarcoplasmic reticulum calcium handling during diabetic cardiomyopathyKranstuber, Allyson Leigh 17 December 2012 (has links)
No description available.
|
35 |
Modélisation du microenvironnement tumoral : impact du collagène de type I sur la migration de la cellule tumorale et sur sa réponse à la chimiothérapie / Modélisation du microenvironnement tumoral : impact du collagène de type I sur la migration de la cellule tumorale et sur sa réponse à la chimiothérapieSaid, Georges 28 September 2012 (has links)
Le microenvironnement tumoral via les macromolécules matricielles est connu pour jouer un rôle clé dans la réponse des cellules cancéreuses à la chimiothérapie en favorisant leur survie et leur prolifération. L'impact du collagène de type I, protéine matricielle majeure du microenvironnement, a été évalué au niveau des capacités migratoires des cellules tumorales et de leur réponse aux agents anticancéreux, doxorubicine et metformine. Cette approche a étémenée chez des cellules humaines HT1080 hautement invasives au moyen de systèmes de culture par coating 2D ou en matrice 3D. Les effets de modifications post-traductionnelles du collagène comme la carbamylation et de la glycation ont été également étudiées. Les résultats montrent que le collagène 3D inhibe l'activité anti-migratoire de la doxorubicine. Cette protection met en jeuune préservation des niveaux d'activation de FAK et RhoA impliquées dans la formation des fibres de stress d'actine et des plaques d'adhésion focales. Le collagène glyqué 2D et dans une moindre mesure le carbamylé inhibent l'adhésion, la migration des cellules tumorales et désorganisent leur cytosquelette d'actine via des modifications de distribution de la vinculine, de FAK et des intégrines 1. Cet impact de la glycation a été aussi mis en évidence en matrice 3D après modification du processus de glycation. Enfin, la glycation exerce un effet protecteur vis-àvis des capacités anti-prolifératives et anti-migratoires de la doxorubicine et de la metformine. En conclusion, nous mettons en évidence une nouvelle forme de résistance CAM-DR dirigée contre l'activité anti-invasive de médicaments ; cet effet pouvant être généré par une protéine matricielle native ou modifiée lors de situations physiopathologiques associées au cancer. / The tumor microenvironment via the extracellular matrix plays an important role in cancer cell response to chemotherapy by promoting their survival and proliferation. In this work, we studied the impact of collagen type I, a major matrix protein of tumor microenvironment, on the migration capacities of tumor cells and on their response to anticancer drugs such as doxorubicin and metformin. This approach was performed with the highly invasive human cell line HT1080,by means of 2D coating or 3D matrix cell culture systems. The effects of collagen posttranslational modifications such as carbamylation and glycation were also assessed. The results show that the 3D collagen inhibits the anti-migratory effect of doxorubicin. This protection is carried out through the preservation of the activation states of FAK and RhoA, which are involved in the formation of actin stress fibers and focal adhesions. On 2D coating, the glycated collagen and at a lesser extent the carbamylated one decrease the adhesion, the migration oftumor cells and, disorganize the actin cytoskeleton via a modified distribution of vinculine, FAK and beta1 integrins. This impact is also demonstrated by using 3D matrices, after adaptation of the glycation process. In addition, we reported that the glycated collagen protects against the antiproliferative and the anti-migratory effects of doxorubicin and metformin. In conclusion, we highlighted a new form of CAM-DR resistance that targets the drugs anti-invasive activity. This impact could be induced by the native form of matrix proteins or the modified one found inpathological situations which are associated to cancer.
|
36 |
Stress oxydant et glycoxydation : impact des produits avancés de glycation sur les mitochondries des cellules endothéliales dans le cadre de la pathologie diabétique / Oxidative stress and glycoxidation : impact of advanced glycation end products on mitochondria of endothelial cells in diabetesDobi, Anthony 28 June 2018 (has links)
L’endothélium est une barrière semi-perméable assurant le maintien de l’homéostasie vasculaire. C’est un régulateur clé du tonus vasculaire, des processus de coagulation et de fibrinolyse, et de l’inflammation. Sa dysfonction est à l’origine de nombreuses pathologies parmi lesquelles figurent les complications vasculaires liées au diabète, notamment les maladies cardiovasculaires, première cause de mortalité chez les patients diabétiques. Le stress oxydant associé aux produits avancés de glycation (AGEs), dont la formation est favorisée par l’hyperglycémie, constitue l’élément central de la dysfonction endothéliale. Ce stress correspond à un déséquilibre entre les défenses antioxydantes et les espèces prooxydantes cellulaires en faveur de ces dernières, et peut être d’origine mitochondriale. L’objectif de mon travail de thèse a été de déterminer les effets des AGEs dérivant de l’albumine (la protéine plasmatique la plus abondante) sur le fonctionnement des mitochondries de cellules endothéliales en culture, en parallèle à une analyse des mécanismes moléculaires impliqués dans le stress oxydant intracellulaire, et des fonctions endothéliales. L’étude mitochondriale s’est principalement axée sur la description des états respiratoires et a révélé des phénotypes associés aux AGEs, variant en fonction du modèle cellulaire endothélial et de la confluence. Par ailleurs, deux autres résultats phares issus de mes investigations correspondent à la mise en évidence de : 1) l’altération des propriétés antioxydantes de l’albumine, ainsi que l’acquisition d’un pouvoir pro-oxydant après glycoxydation ; 2) la contribution des mitochondries au stress oxydant, à travers une communication possible avec la NADPH oxydase, une enzyme produisant des anions superoxydes. Ce travail apporte ainsi un nouvel éclairage sur le déséquilibre redox observé chez les cellules endothéliales dans le cadre de la pathologie diabétique, en relation avec l’aspect mitochondrial. / The endothelium ensures the maintenance of vascular homeostasis. It is a fundamental regulator of vascular tone, coagulation, fibrinolysis, and inflammation. Its dysfunction mediates numerous pathologies, including, among others, diabetes vascular complications, particularly cardiovascular diseases, the major cause of mortality in diabetic patients.Oxidative stress related to advanced glycation end products (AGEs), whose formation is enhanced by hyperglycemia, represents the central element of endothelial dysfunction. This stress is defined as “an imbalance between oxidants and anti-oxidants in favor of the oxidants”, and can originate from mitochondria. The objective of my thesis was to determine the effects of AGEs derived from albumin (the most abundant protein in plasma) on mitochondria of cultured endothelial cells, in parallel to an analysis of the molecular mechanisms involved in intracellular oxidative stress, and endothelial functions.Mitochondrial exploration mainly focused on the description of the respiratory states and revealed AGEs-associated phenotypes, depending on endothelial cell model and cell confluence. Furthermore, two other key results from my investigations correspond to the highlighting of: 1) the alteration of albumin antioxidant properties, as well as the acquisition of a pro-oxidant capacity after glycoxidation processes; 2) the involvement of mitochondria in oxidative stress, through a potential communication with NADPH oxidase, an enzyme that produces superoxide anions.This work brings novel insights into the redox imbalance observed in endothelial cells during diabetes, in relation to the mitochondrial aspect.
|
37 |
The role of a deglycating enzyme 'fructosamine-3-kinase' in diabetes and COPDAlderawi, Amr Saleh January 2017 (has links)
Recent statistics show that approximately 415 million people worldwide have diabetes. Glycated haemoglobin (HbA1c) measurements were introduced many years ago as the gold standard tool for detecting and monitoring treatment as well as making management decisions for diabetic patients. Glycated haemoglobins are formed by the non-enzymatic glycation of haemoglobin molecules. This non-enzymatic glycation process has been strongly related to pathogenesis of chronic complications associated to diabetes. It was suggested that this glycation process may be moderated by an enzymatic deglycation process thought to involve a deglycating enzyme known as Fructosamine-3-kinase (FN3K), an enzyme that deglycates the glycated haemoglobin in erythrocytes and other glycated proteins in other tissues. FN3K acts through phosphorylation of fructosamines on the third carbon of their sugar moiety, making them unstable and consequently causing them to detach from the protein. The degree of deglycation is thought to depend on the activity of the FN3K enzyme. Moreover, variation in the activity of FN3K between individuals is hypothesised to lead to apparent differences in glycated haemoglobin levels: some individuals have high rates of deglycation so that they tend to have lower average glycaemia than actually the case, while others with low rates of deglycation appear to have higher than actual glycaemia (known as the glycation gap, G-gap). The G-gap has been reported to be associated with alteration of diabetic complications risk. The G-gap reflects the discrepancy between average glycaemia as determined from glycated haemoglobin (measured as HbA1c) and that from the determination of fructosamine. The positive G-gap is defined as a higher level of glycation of proteins than expected whereas a negative G-gap means a lower level of glycation than expected. To explore the role of FN3K in diabetes and other associated morbidities, we decided to divide our research into 3 studies. Each study was categorised according to the type and the source of samples involved. The first study explored the correlation between FN3K activity and protein level with G-gap data; it involved 148 diabetic patients who were recruited at New Cross Hospital, Wolverhampton, selected as having a consistent positive G-gap > +0.5 and a consistent negative G-gap > -0.5 over a minimum of 2 estimations. Age, gender, race and BMI were collected from patients in this study. Blood samples were also 3 collected to measure FN3K activity, protein levels, and markers of CVD in relation to G-gap. The second study involved 23 AECOPD patients who were recruited from St George’s Hospital (London) and were treated with either metformin or a placebo. Serum samples were collected from these patients for a larger study: we assayed those 23 serum samples for FN3K protein levels to explore any possible correlation between FN3K with metformin therapy in COPD patients. The third study utilised 36 human peripheral lung samples from healthy individuals, asymptomatic smokers and stable COPD patients (GOLD 2) who were recruited at The Section of Respiratory Medicine, University Hospital of Ferrara, Italy. Those samples were assessed for FN3K expression by means of immunohistochemistry to explore the difference in FN3K activity between those three categories. It was found that the intracellular activity and protein expression of the FN3K enzyme in diabetic patients negatively correlated with the values of G-gaps where FN3K activity was high in patients with negative G-gap. FN3K serum protein levels were shown to be enhanced with metformin administration in COPD diabetic patients, suggesting a protective role for FN3K enzyme against protein damaged caused by the non-enzymatic glycation of proteins. Therefore, patients with positive G-gap have lower FN3K activity than those with negative G-gap, and in turn they are more susceptible to diabetes related complications. Our data also indicate that metformin has a beneficial effect in reducing damage caused by carbonyl stress from cigarette smoking in COPD patients by the action of FN3K. Our research has demonstrated that FN3K contributes to the protein repair system which protects against damage caused by non-enzymatic glycation. The high activity for the FN3K enzyme was associated with low levels of AGEs and low carbonyl stress levels in observed among patients with diabetes and COPD. In contrast, COPD patients tend to have low FN3K-mediated protection against protein damage in comparison to the normal population. These patients tend to be at risk for developing more complications, particularly CVD complications, than normal, healthy individuals. Treatment with metformin enhances FN3K action in COPD diabetic patients, possibly as a protective enzyme against the damaged caused by the non-enzymatic glycation.
|
38 |
Marqueurs d'athérothrombose carotidienne chez le diabétique de type 2 : rôle du stress oxydant dans la vulnérabilité de la plaque / Markers of carotid atherothrombosis in type 2 diabetic patients : role of oxidative stress in plaque vulnerabilityCatan, Aurélie 27 September 2018 (has links)
Sur l’île de La Réunion, la prévalence du diabète de type 2 est 3,5 fois plus élevée que celle de la France hexagonale. Parmi les diverses complications qu’engendre le diabète, les AVC qui en résultent sont responsables d’une forte mortalité faisant des maladies cardiovasculaires un problème de santé publique majeur sur l’île. Les AVC ischémiques proviennent de l’occlusion d’une artère cérébrale par un thrombus généré localement ou qui s’est détaché d’une plaque d’athérothrombose généralement localisée au niveau des bifurcations carotidiennes. Les plaques compliquées sont souvent caractérisées par des hémorragies intraplaques, responsables de l’extravasation des cellules sanguines. Différents marqueurs moléculaires, protéiques et physiques peuvent refléter ces processus et renseigner le médecin sur l’instabilité de la plaque du patient. Il est donc important d’étudier ces marqueurs de risque de rupture de plaques carotidiennes chez les patients diabétiques, afin d’en prévenir les complications et la mortalité associée. L’hémorragie intraplaque, notamment pourvoyeuse d’érythrocytes et de neutrophiles libérant leurs contenus cytoplasmiques, participe activement à la déstabilisation de la plaque d’athérothrombose chez le diabétique. Cette thèse a permis l’étude de l’influence de ces marqueurs à travers une étude clinique et de proposer un nouveau concept de phagocytose des érythrocytes glyqués par les cellules endothéliales in vitro. Ainsi, les résultats préliminaires de l’étude clinique nous permettent de supposer que la clairance des globules rouges des patients diabétiques est altérée, ce qui leurs permettraient de résider sur une période plus longue dans les plaques de ces patients. De cette manière, les globules rouges pourraient y être pris en charge par d’autres types cellulaires comme les cellules endothéliales. Nous avons tout d’abord mis au point un modèle de glycation des érythrocytes in vitro reflétant un diabète mal équilibré. Nous avons ensuite mis en évidence que les globules rouges glyqués pouvaient être phagocytés par les cellules endothéliales humaines, conduisant à une prolifération limitée et à la surexpression de l’HO-1. Ces données suggèrent qu’une ingestion des érythrocytes glyqués par les cellules endothéliales pourrait amplifier la déstabilisation des plaques d’athérothrombose carotidiennes des diabétiques. / Type 2 diabetes prevalence in Reunion Island, a French overseas department, is 3.5 higher than in France mainland. Among the various diseases caused by diabetes, stroke induces high mortality making cardiovascular diseases a major public health problem on the island. Ischemic stroke results from a cerebral artery occlusion by a thrombus that is locally produced or has detached from an atherothrombotic plaque usually located at the carotid bifurcations. Complicated plaques can are often characterized by intraplaque hemorrhages, responsible for blood cell extravasation. Several molecular and physical markers can reflect these processes and inform the physician about the instability of the patient's plaque. It is therefore of major importance to study the markers of carotid plaque rupture in diabetic patients in order to prevent complications and associated mortality. Intraplaque hemorrhage, providing erythrocytes and neutrophils releasing their cytoplasmic contents, plays an active role in destabilizing atherothrombotic plaque in diabetic subjects. The objectives of the present thesis were to study these markers in a clinical study and to suggest a new concept of red blood cell phagocytosis by endothelial cells in vitro. According to the first results of the clinical study, we can suggest that in diabetic patients, the clearance of red blood cells is impaired. This prolonged residence of red blood cells in atherosclerotic plaques from diabetic patients. In this way, red blood cells could be phagocytosed by othercell types such as endothelial cells. In this work, we have also set up an in vitro model of erythrocyte glycation that reflects a clinical situation of poorly controlled diabetes. We have demonstrated that glycated red blood cell phagocytosed by human endothelial cells, leading to their limited proliferation and to HO-1 overexpression. These data suggest an ingestion of glycated erythrocytes by endothelial cells may amplify the destabilization of carotid atherothrombotic plaques in diabetics.
|
39 |
Stress oxydant et pathologie diabétique à l’île de La Réunion – Identification et caractérisation des propriétés structurales et fonctionnelles de l’albumine glyquée / Oxidant stress and diabetes – Deciphering structural and functional impacts of glycoxidation on human albuminBaraka-Vidot, Marie-Jennifer 03 December 2014 (has links)
La glycoxydation est un processus délétère directement impliqué dans la pathologie diabétique. Ce phénomène touche principalement les protéines circulantes. Une des cibles majoritaires de ce phénomène est l'albumine, protéine plasmatique la plus abondante. L'objectif de ce travail de thèse vise une meilleure compréhension du phénomène de glycoxydation dans le diabète. Pour cela, les conséquences fonctionnelles et physiologiques liées aux altérations structurales et biochimiques de l'albumine glyquée ont été étudiées, à travers la comparaison d'un modèle d'albumine glyquée in vivo purifiée de patients diabétiques avec celui correspondant à la protéine glyquée par un processus in vitro. Notre étude montre des modifications de type structural et oxydatif attestées par des mesures de fluorescence (accessibilité du tryptophane) et de groupements spécifiques comme les fructosamines, les amines primaires, résidus thiols et carbonyles. D'un point de vue fonctionnel, l'albumine glyquée purifiée de patients diabétiques exerce, sur des cultures cellulaire, un effet proinflammatoire et prooxydant, encore plus marqué que ne le fait l'albumine glyquée in vitro. Également, les capacités de liaison de l'albumine avec les médicaments ainsi que l'activité estérase diminuent avec le phénomène de glycation. Les résultats de cette étude apportent de nouveaux éléments de compréhension sur le phénomène de glycation de l'albumine tel qui pourrait apparaitre dans la pathologie diabétique et ouvre de nouvelles pistes d'études sur l'impact réel des AGEs issus de l'albumine dans des désordres physiologiques inhérents à cette pathologie. / Albumin constitutes the major circulating protein in blood and represents a very beneficial biological actor through its multifunctional properties such as antioxidant activities and drug binding capacities. But, in hyperglycemic conditions, such as those encountered in diabetes, albumin can undergo glycoxidative modifications which may impact the protein quality. Objectives of my thesis were to clarify the impact of glycoxidative modification of albumin on its structure and its functions and to determine whether such impairments may be encountered in albumin purified from diabetics. The occurrence of structural and oxidative modifications were found to be enhanced in in vitro glycoxidized HSA and albumin purified from diabetics, after determination of their free thiol group content, relative electrophoretic migration, carbonyl content, fructosamines and antioxidant activities. In addition, glycoxidized albumins exhibited impaired pharmaceutic molecule binding capacities and reduced esterase activities. Also, cells treated with glycoxidized albumin purified from diabetics, exhibited a proinflammatory state even more exacerbated than those incubated with in vitro glycated albumins. We evidenced the triggering action of metals (copper and iron) on glycoxidative-induced modifications in albumin. This work needs further studies and opens doors to many perspectives aiming to reach a better understanding of glycoxidative modification of albumin in diabetic patients.
|
40 |
Etude de la capacité d'inhibition de l'apolipoprotéine C1 sur l'activité de la protéine de transfert des esters de cholestérol chez des patients coronariens normolipidémiques et hyperlipidémiques et chez des patients diabétiques / Study of the ability of apolipoprotein C1 to inhibit cholesteryl ester transfer protein activity in normolipidemic and hyperlipidemic patients with coronary artery disease and in patients with diabetesBouillet, Benjamin 24 October 2013 (has links)
Une augmentation de l’activité de la protéine de transfert des esters de cholestérol (CETP) est retrouvée associée à une élévation du développement de l’athérosclérose. L’apolipoprotéine C1 est l’inhibiteur physiologique de la CETP. Ses propriétés électrostatiques jouent un rôle important dans sa capacité d’inhibition de l’activité CETP. Aucune étude de ce potentiel inhibiteur de l’apoC1 n’a été réalisée chez des patients à haut risque cardio-vasculaire ou dyslipidémiques. Nous avons souhaité étudier la fonctionnalité de l’apoC1 par rapport à la CETP chez des patients coronariens normolipidémiques et hyperlipidémiques d’une part et chez des patients diabétiques de type 1 et de type 2 en comparaison à des sujets sains normolipidémiques d’autre part. Nous avons confirmé que l’apoC1 était un inhibiteur physiologique de la CETP chez l’homme normolipidémique. Nous avons montré pour la première fois la perte de cette capacité d’inhibition en cas d’hyperlipidémie chez des sujets coronariens et en cas de diabète de type 1 ou de type 2.En cas d’hyperlipidémie, l’hypertriglycéridémie joue un rôle important en stimulant la réaction de transfert des esters de cholestérol. La possible modification de répartition de l’apoC1 entre HDL et VLDL secondaire à l’hyperlipidémie est probablement également impliquée dans cette perte de fonctionnalité. Au cours du diabète, notamment de type 1, nous avons démontré que l’hyperglycémie, à l’origine du phénomène de glycation, participe, au moins en partie, à cette perte de potentiel inhibiteur. Nous avons également mis en évidence que la glycation in vitro de l’apoC1 modifiait sa charge électrostatique, facteur déterminant de son potentiel inhibiteur. / High cholesteryl ester transfer protein (CETP) activity was found to accelerate the progression of atherosclerosis. Apolipoprotein C1 (apoC1) is a potent physiological inhibitor of CETP. ApoC1 operates as CETP inhibitor through its ability to modify the electrostatic charge at the lipoprotein surface. The inhibitory potential of apoC1 has never been studied in high risk patients or in patients with hyperlipidemia. Our aim was to address the functionality of apoC1 as CETP inhibitor in normo- and hyperlipidemic patients with documented coronary artery disease and in patients with type 1 and type 2 diabetes in comparison with normolipidemic-normoglycemic healthy subjects. We confirmed that apoC1 is a physiological inhibitor of CETP in normolipidemic subjects. We showed for the first time that this inhibitory potential is lost in hyperlipidemic patients with coronary artery disease and in patients with type 1 or type 2 diabetes. During hyperlipidemia, abundant triglyceride-rich lipoproteins, as preferential acceptors of HDL cholesteryl ester, probably drive the CETP-mediated cholesteryl ester transfer reaction. The modified distribution of apoC1 between HDL and VLDL might play a role in this loss of inhibitory property. During diabetes, especially in type 1, we showed that hyperglycemia, responsible for glycation, is involved, at least in part, in this loss of CETP inhibitory ability of apoC1. We also showed that in vitro glycation of apoC1 changed its electrostatic properties, which is recognized as a major determinant of its inhibitory ability.
|
Page generated in 0.1106 seconds